No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Shandong Wit Dyne Health Co., Ltd., founded on June 26, 1993, and headquartered in Jinan, China, dedicates its operations to the investigation, creation, and manufacture of pharmaceuticals and health solutions tailored for children. The company offers a wide array of products, which include vitamin A and D drops, effervescent granules containing compound calcium carbonate, licorice zinc granules, iron dextran granules, and pediatric ibuprofen suppositories. Its offerings further extend to specialized medications such as azithromycin granules, dimercaptosuccinic acid capsules, rifaximin dry suspension, and oral rehydration salt powder.
www.sd-wit.comNo one on the platform currently holds 000915.SZ.
No tracked institution reports a position in 000915.SZ as of their last filing.
No one on the platform has traded 000915.SZ yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 106.9% | 100.7% | 77.2% | — | — | — |
| Rev. Growth % | 4.4% | 4.1% | ||||
| Profit Margin % | 24.0% | 22.6% | 17.5% | |||
| Free Cash Flow Margin % | 54.9% | 44.1% | 31.7% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $2.1B | -7.6% | $2.16 | $2.16–$2.16 | — | 1 |
| 2027 | $2.3B | +5.6% | $2.31 | $2.31–$2.31 | — | 1 |
| 2028 | $2.4B | +5.3% | $2.46 | $2.46–$2.46 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| $5.53 |
| -0.72% |
| $5.7B |
| — |
| 002424.SZGuizhou Bailing Group Pharmaceutical Co., Ltd. | $4.43 | -0.45% | $6.2B | — |
| 002437.SZHarbin Gloria Pharmaceuticals Co., Ltd | $3.36 | +0.30% | $7.5B | — |
Source: Financial Modeling Prep · peers by sector/industry